Funds and ETFs Hikma Pharmaceuticals PLC

HIK

GB00B0LCW083

Name	Weight	AuM	1st Jan change	Investor Rating
HARTFORD MULTIFACTOR DEVELOPED MARKETS (EX-US) ETF - USD	0.44%	0 M€	+3.57%
FRANKLIN LIBERTYQ EUROPEAN EQUITY UCITS ETF - EUR	0.25%	3 M€	+9.95%	-
ISHARES CURRENCY HEDGED MSCI UNITED KINGDOM ETF - USD	0.20%	11 M€	+0.83%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	0.16%	0 M€	+7.69%	-
ISHARES EDGE MSCI MULTIFACTOR EAFE INDEX ETF (CAD-HEDGED) - CAD	0.15%	5 M€	+10.09%	-
ISHARES EDGE MSCI MULTIFACTOR EAFE INDEX ETF - CAD	0.15%	14 M€	+5.66%	-
UBS (IRL) ETF PLC MSCI EUROPE ESG UNIVERSAL LOW CARBON SELECT UCITS ETF - ACC - EUR	0.04%	6 M€	-.--%
SIMPLIFY DEVELOPED EX-US PLUS DOWNSIDE CONVEXITY ETF - USD	0.02%	10 M€	-3.35%	-
DAY HAGAN/NED DAVIS RESEARCH SMART SECTOR INTERNATIONAL ETF - USD	0.01%	0 M€	+7.24%	-
AMUNDI MSCI WORLD CLIMATE PARIS ALIGNED PAB UCITS ETF DR (C) - USD	0.01%	284 M€	-.--%
LYXOR MSCI WORLD CLIMATE CHANGE (DR) UCITS ETF - ACC - USD	0.01%	206 M€	-.--%
AMUNDI INDEX MSCI WORLD UCITS ETF - EUR	0.01%	1,166 M€	+0.26%
AMUNDI INDEX MSCI WORLD UCITS ETF DR (D) - EUR	0.01%	607 M€	+0.05%
AMUNDI MSCI WORLD CLIMATE TRANSITION CTB UCITS ETF DR (C) - EUR	0.01%	786 M€	-.--%
AMUNDI MSCI WORLD CLIMATE TRANSITION CTB UCITS ETF DR (C) - USD	0.01%	23 M€	-.--%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (UNHEDGED) ETF - JPY	0.01%	0 M€	+18.92%
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF ACC - EUR	0.00%	0 M€	+8.70%	-
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD	0.00%	0 M€	+3.63%	-
IMGP RBA RESPONSIBLE GLOBAL ALLOCATION ETF - USD	0.00%	7 M€	+0.11%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.00%	0 M€	+8.24%	-
ADAPTIVE GROWTH OPPORTUNITIES ETF - USD	0.00%	0 M€	+2.72%	-
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - ACC - EUR	0.00%	0 M€	+5.79%	-
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.00%	0 M€	+5.63%	-
CI MARRET ALTERNATIVE ABSOLUTE RETURN BOND ETF - CAD	0.00%	0 M€	-3.22%	-

Hikma Pharmaceuticals PLC specializes in developing, producing, and selling drugs used in treating cardiovascular diseases, infections, cancers, diabetes, etc. Net sales break down by family of products as follows: - generic injectable products (45.3%); - brand name drugs (27.5%); - generic products taken orally (26.7%); - other (0.5%). Net sales are distributed geographically as follows: the United Kingdom (0.3%), the United States (56.9%), Middle East and North Africa (34.4%) and other (8.4%).

Sector

Pharmaceuticals

Calendar

2024-05-13 - RBC Capital Markets Global Healthcare Conference

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Ratings for Hikma Pharmaceuticals PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

24.95 USD

Average target price

28.68 USD

Spread / Average Target

+14.92%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HIKMA PHARMACEUTICALS PLC	+11.46%	5.54B
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B

Other Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:01 2024-05-10 am EDT			5-day change	1st Jan Change
1,994 ^GBX	+0.66%		+1.73%	+11.46%

May. 03	Deutsche Bank Starts Hikma Pharmaceuticals Coverage at Buy	MT
May. 03	Jefferies cuts AJ Bell; Deutsche likes ConvaTec	AN